Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-18T02:14:41.338Z Has data issue: false hasContentIssue false
  • English
  • Français

Effects of Paroxetine on Motor and Cognitive Function Recovery in Patients with Non-Depressed Ischemic Stroke: An Open Randomized Controlled Study

Published online by Cambridge University Press:  30 May 2018

Xiao-Ling Pan ,
Hong-Fang Chen ,
Xing Cheng ,
Chuan-Chen Hu ,
Jian-Wei Wang ,
Ya-Ming Fu ,
Hui-Mei Kong  and
Hui-Jun Shao
Xiao-Ling Pan
Affiliation:
Department of Neurology, Jinhua Hospital Affiliated to Zhejiang University, Jinhua, China
Hong-Fang Chen
Affiliation:
Department of Neurology, Jinhua Hospital Affiliated to Zhejiang University, Jinhua, China
Xing Cheng
Affiliation:
Department of Neurology, Jinhua Hospital Affiliated to Zhejiang University, Jinhua, China
Chuan-Chen Hu
Affiliation:
Department of Neurology, Jinhua Hospital Affiliated to Zhejiang University, Jinhua, China
Jian-Wei Wang
Affiliation:
Department of Neurology, Jinhua Hospital Affiliated to Zhejiang University, Jinhua, China
Ya-Ming Fu
Affiliation:
Department of Neurology, Jinhua Hospital Affiliated to Zhejiang University, Jinhua, China
Hui-Mei Kong
Affiliation:
Department of Neurology, Jinhua Hospital Affiliated to Zhejiang University, Jinhua, China
Hui-Jun Shao*
Affiliation:
Department of Neurology, Jinhua Hospital Affiliated to Zhejiang University, Jinhua, China
*
Address for correspondence: Hui-Jun Shao, Department of Neurology, Jinhua Hospital Affiliated to Zhejiang University, Jinhua, 321000, China. E-mail: dochuijunshao@126.com
Get access

Abstract

Introduction: To investigate the effects of paroxetine (PAR) on motor and cognitive function recovery in patients with non-depressed ischemic stroke (nD-AIS).

Methods: One hundred sixty-seven patients hospitalized for non-depressed acute ischemic stroke were selected and divided into treatment (T) and control (C) groups using a random number table. All patients received conventional secondary ischemic stroke prevention and rehabilitation training; patients in Group T additionally received treatment with PAR (10 mg/day during week 1 and 20 mg/day thereafter) for 3 months. The follow-up observation lasted 6 months. The Fugl–Meyer motor scale (FMMS), Montreal cognitive assessment (MoCA), and Hamilton depression scale (HAMD) were used on D0, D15, D90, and D180 (T0, 1, 2, and 3, respectively; D180 = 90 days after treatment cessation) after study initiation, and scores were compared between the groups.

Results: The FMMS and MoCA scores differed significantly between Groups T and C at T2 and T3 (p < .05); by contrast, these scores did not differ significantly between the groups at T1 (p > .05). Furthermore, the HAMD scores differed significantly between the two groups at T3 (p < .05), but not at T1 and T2 (p > .05).

Conclusions: PAR treatment may improve motor and cognitive function recovery in patients with nD-AIS. Moreover, PAR may reduce the occurrence of depression after stroke.

Keywords

Cognitiveischemic strokemotorparoxetinerecovery
Type
Articles
Information
Brain Impairment , Volume 19 , Issue 3 , December 2018 , pp. 228 - 234
Copyright
Copyright © Australasian Society for the Study of Brain Impairment 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allaman, I., Fiumelli, H., Magistretti, P.J., & Martin, J.L. (2011). Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology (Berl), 216, 75–84.Google Scholar
Ampuero, E., Rubio, F.J., Falcon, R., Sandoval, M., Diaz-Veliz, G., Gonzalez, R.E., & Wyneken, U. (2010). Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex. Neuroscience, 169, 98–108.Google Scholar
Bilge, C., Koçer, E., Koçer, A., & TürkBörü, U. (2008). Depression and functional outcome after stroke: The effect of antidepressant therapy on functional recovery. European Journal of Physical and Rehabilitation Medicine, 44, 13–18.Google Scholar
Chen, Z. (2008). A survey of the third cause of death in China. China union medical university press; pp. 208–210.Google Scholar
Chollet, F., Tardy, J., Albucher, J.F., Thalamas, C., Berard, E., Lamy, C., & Loubinoux, I. (2011). Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): A randomised placebo-controlled trial. Lancet Neurology, 10, 123–130.Google Scholar
Cramer, S.C. (2008). Repairing the human brain after stroke: I. Mechanisms of spontaneous recovery. Annals of Neurology, 63, 272–287.Google Scholar
Espinera, A.R., Ogle, M.E., Gu, X., & Wei, L. (2013). Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice. Neuroscience, 247, 1–11.Google Scholar
Guirado, R., Varea, E., Castillo-Gómez, E., Gómez-Climent, M.A., Rovira-Esteban, L., Blasco-Ibáñez, J.M., & Nàcher, J. (2009). Effects of chronic fluoxetine treatment on the rat somatosensory cortex: Activation and induction of neuronal structural plasticity. Neuroscience Letters, 457, 12–15.Google Scholar
Homberg, J.R., Olivier, J.D., Blom, T., Arentsen, T., van Brunschot, C., Schipper, P., & Reneman, L. (2011). Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. PLoS One, 6, e16646.Google Scholar
Jin, H., Ding, B.R., Yang, X., Lei, Z.H., Zeng, X.L., Bai, S., & Tu, Q.Y. (2011). The utility of Beijing version montreal cognitive assessment in ischemic cerebrovascular disease patients of Chansha area and the development of Changsha version montreal cognitive assessment. Chinese Journal of Nervous and Mental Disease, 37, 349–353.Google Scholar
Jones, T.A., & Adkins, D.L. (2010). Behavioral influence on neuronal events after stroke. In Cramer, S.C. & Nudo, R.J. (Eds.), Brain repair after stroke[M] (pp. 23–33). Cambridge, UK: Cambridge University Press.Google Scholar
Jones, T.A., Allred, R.P., Adkins, D.L., Hsu, J.E., O'Bryant, A., & Maldonado, M.A. (2009). Remodeling the brain with behavioral experience after stroke. Stroke, 40, S136–S138.Google Scholar
Jorge, R.E., Acion, L., Moser, D., Adams, H.P., & Robinson, R.G. (2010). Escitalopram and enhancement of cognitive recovery following stroke. Archives of General Psychiatry, 67, 187–196.Google Scholar
Kraglund, K.L., Mortensen, J.K., Grove, E.L., Johnsen, S.P., & Andersen, G. (2015). TALOS: A multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke. International Journal of Stroke, 10, 985–987.Google Scholar
Liu, X., Zhang, J., Sun, D., Fan, Y., Zhou, H., & Fu, B. (2014). Effects of fluoxetine on brain-derived neurotrophic factor serum concentration and cognition in patients with vascular dementia. Clinical Interventions in Aging, 10, 411–418.Google Scholar
Martí-Fàbregas, J., Romaguera-Ros, M., Gómez-Pinedo, U., Martínez-Ramírez, S., Jiménez-Xarrié, R., Marín, E., & Garcia-Verdugo, J.M. (2010). Proliferation in the human ipsilateralsubventricular zone after ischemic stroke. Neurology, 17, 134– 135.Google Scholar
Mikami, K., Jorge, R.E., Adams, H.P., Davis, P.H., Leira, E.C., Jang, M., & Robinson, R.G. (2011). Effect of antidepressants on the course of disability following stroke. American Journal of Geriatric Psychiatry, 19, 1007–1015.Google Scholar
Mortensen, J.K., & Andersen, G. (2015). Safety of selective serotonin reuptake inhibitor treatment in recovering stroke patients. Expert Opinion on Drug Safety, 14, 911–919.Google Scholar
Rayen, I., van den Hove, D.L., Prickaerts, J., Steinbusch, H.W., & Pawluski, J.L. (2011). Fluoxetine during development reverses the effects of prenatal stress on depressive-like behavior and hippocampal neurogenesis in adolescence. PLoS One, 6, e24003.Google Scholar
Rossini, P.M., Calautti, C., Pauri, F., & Baron, J.C. (2003). Post-stroke plastic reorganization in the adult brain. Lancet Neurol, 2, 493–502.Google Scholar
Sato, S., Kawamata, T., Kobayashi, T., & Okada, Y. (2014). Antidepressant fluvoxamine reduces cerebral infarct volume and ameliorates sensorimotor dysfunction in experimental stroke. Neuroreport, 25, 731–736.Google Scholar
Siepmann, T., Penzlin, A.I., Kepplinger, J., Illigens, B.M., Weidner, K., Reichmann, H., & Barlinn, K. (2015). Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: Possible mechanisms and clinical evidence. Brain and Behavior, 5, e00373.Google Scholar
Tan, J.P., Li, N., Gao, J., Wang, L.N., Zhao, Y.M., Yu, B.C., & Zhou, P.Y. (2015). Optimal cutoff scores for dementia and mild cognitive impairment of the Montreal Cognitive Assessment among elderly and oldest-old Chinese population. Journal of Alzheimer's Disease, 43, 1403–1412.Google Scholar
Wang, Y., Liao, X., Zhao, X., Wang, D.Z., Wang, C., Nguyen-Huynh, M.N., & Wang, Y. (2011). Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: Analysis of the results from the Chinese National Stroke Registry (CNSR). Stroke, 42, 1658–1664.Google Scholar